Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.5 GBX | +0.70% | +3.62% | +43.00% |
Mar. 26 | EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend | AN |
Mar. 26 | BATM Advanced ink USD2.3 million orders | AN |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 38.15 | 38.39 | 65.06 | 62.63 | 47.09 | 75.67 | - |
Enterprise Value (EV) 1 | 38.15 | 31.37 | 70.44 | 70.91 | 47.09 | 77.02 | 75.95 |
P/E ratio | -2.16 x | - | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 6.13 x | 2.59 x | 4.96 x | 3.89 x | 2.6 x | 2.36 x | 1.71 x |
EV / Revenue | 6.13 x | 2.12 x | 5.37 x | 4.4 x | 2.6 x | 2.4 x | 1.71 x |
EV / EBITDA | - | -4.14 x | -9.32 x | -11.1 x | 15.7 x | -46.6 x | 17.4 x |
EV / FCF | - | - | - | -5.52 x | - | -21.5 x | 32.1 x |
FCF Yield | - | - | - | -18.1% | - | -4.65% | 3.12% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 91,933 | 80,822 | 80,822 | 94,183 | 94,183 | 105,837 | - |
Reference price 2 | 0.4150 | 0.4750 | 0.8050 | 0.6650 | 0.5000 | 0.7150 | 0.7150 |
Announcement Date | 5/15/20 | 4/19/21 | 4/29/22 | 3/15/23 | 3/26/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 6.224 | 14.83 | 13.12 | 16.12 | 18.13 | 32.08 | 44.34 |
EBITDA 1 | - | -7.583 | -7.558 | -6.375 | 3 | -1.654 | 4.368 |
EBIT 1 | - | -8.382 | -8.352 | -7.971 | -7.226 | -4.654 | 1.368 |
Operating Margin | - | -56.51% | -63.68% | -49.45% | -39.85% | -14.51% | 3.09% |
Earnings before Tax (EBT) 1 | - | -8.927 | -8.422 | -8.02 | -7.339 | -4.484 | 1.368 |
Net income | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - |
EPS | -0.1920 | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -12.85 | - | -3.584 | 2.368 |
FCF margin | - | - | - | -79.74% | - | -11.17% | 5.34% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | 54.21% |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 5/15/20 | 4/19/21 | 4/29/22 | 3/15/23 | 3/26/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | 5.38 | 8.27 | - | 1.35 | 0.28 |
Net Cash position 1 | - | 7.02 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | -0.7114 x | -1.298 x | - | -0.815 x | 0.0641 x |
Free Cash Flow 1 | - | - | - | -12.9 | - | -3.58 | 2.37 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 5/15/20 | 4/19/21 | 4/29/22 | 3/15/23 | 3/26/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.00% | 94.98M | |
+12.33% | 87.31B | |
-10.19% | 42.87B | |
-12.31% | 28.43B | |
+5.90% | 21.51B | |
-15.85% | 12.22B | |
-9.95% | 10.12B | |
+8.61% | 8.85B | |
-24.60% | 7.89B | |
+8.62% | 5.06B |
- Stock Market
- Equities
- TRU Stock
- Financials TruFin plc